Sorting of circulating tumor cells (MV3-melanoma) and red blood cells using non-inertial lift

Metastasis is the primary cause of death for most breast cancer patients who succumb to the disease. During the haematogenous dissemination, circulating tumor cells interact with different blood components. Thus, there are micro-environmental and systemic processes contributing to cancer regulation. We have published that Red Blood Cells (RBCs) that accompany circulating tumor cells have prognostic value in metastatic breast cancer patients. Although the principal known role of RBCs is gas transport, it has been recently assigned additional functions as regulatory cells on circulation. Hence, to explore their potential contribution to tumor progression, we characterized the proteomic composition of RBCs from 53 breast cancer patients, compared with 33 healthy donors. RBCs from breast cancer patients showed a different proteomic profile compared to healthy donors. The differential proteins were mainly related to extracellular components, proteasome, and metabolism. Besides, LAMP2 emerge as a new RBCs marker with diagnostic and prognostic potential for metastatic patients. Seemingly, RBCs are acquiring modifications in their proteomic composition that probably represents the systemic cancer disease, conditioned by the tumor microenvironment.

Download Full-text

Rapid and simple gas chromatographic measurement of lactic acid in red blood cells, plasma, and tumor cells after hyperthermia

Life Sciences ◽

10.1016/0024-3205(92)90407-g ◽

1992 ◽

Vol 51 (6) ◽

pp. 407-410 ◽

Cited By ~ 2

Author(s):

K. Kageyama ◽

Y. Onoyama ◽

T. Nakajima ◽

M. Tumura ◽

T. Nishida ◽

...

Keyword(s):

Lactic Acid ◽

Red Blood Cells ◽

Tumor Cells ◽

Blood Cells ◽

Chromatographic Measurement

Download Full-text

Interactions Between Circulating Tumor Cells and Aptamer-Functionalized Microposts in a Flow

Volume 7: Fluids Engineering ◽

10.1115/imece2017-70342 ◽

2017 ◽

Author(s):

Kangfu Chen ◽

Teodor Georgiev ◽

Z. Hugh Fan

Keyword(s):

Tumor Cells ◽

Circulating Tumor Cells ◽

Microfluidic Device ◽

Blood Cells ◽

Volume Ratio ◽

Microfluidic Devices ◽

Cancer Prognosis ◽

Device Performance ◽

Simulation Methodology ◽

Geometry Design

Circulating Tumor Cells (CTCs) have been considered as important biomarkers for cancer prognosis and treatment. However, there are only tens of CTCs in one billion of healthy blood cells. This CTC rarity challenge has been addressed by microfluidics technology that sheds light on efficient CTC detection and isolation. Using antibodies or aptamers to capture CTCs is one of the strategies for CTC isolation. A lot of work has been carried out to improve CTC capture efficiency and purity (i.e., specificity). The main consideration to optimize microfluidic device performance includes increasing surface-area-to-volume ratio and reducing shear stress, both of which are closely related to the interaction between CTCs and the microfluidic device. Here we report a detailed study on the interactions between CTCs and aptamer-functionalized microposts in a microfluidic device. We have evaluated the distribution of captured CTCs around a micropost. In addition, simulation was conducted to model CTC capture patterns around microposts. We found the simulated CTC capture pattern largely agree with the experimental results. The simulation methodology could be applicable for other affinity-based CTC isolation devices and approaches. The goal of the study is to improve the microfluidic device performance and provide a rapid and economical way to optimize the geometry design of the microfluidic devices for CTC isolation.

Download Full-text

Extensional flow-based microfluidic device: deformability assessment of red blood cells in contact with tumor cells

BioChip Journal ◽

10.1007/s13206-014-8107-1 ◽

2014 ◽

Vol 8 (1) ◽

pp. 42-47 ◽

Cited By ~ 27

Author(s):

Vera Faustino ◽

Diana Pinho ◽

Tomoko Yaginuma ◽

Ricardo C. Calhelha ◽

Isabel C.F.R. Ferreira ◽

...

Keyword(s):

Red Blood Cells ◽

Tumor Cells ◽

Microfluidic Device ◽

Blood Cells ◽

Extensional Flow

Download Full-text

Fast and Label-Free Isolation of Circulating Tumor Cells from Blood: From a Research Microfluidic Platform to an Automated Fluidic Instrument, VTX-1 Liquid Biopsy System

SLAS TECHNOLOGY Translating Life Sciences Innovation ◽

10.1177/2472630317738698 ◽

2018 ◽

Vol 23 (1) ◽

pp. 16-29 ◽

Cited By ~ 6

Author(s):

Clementine A. Lemaire ◽

Sean Z. Liu ◽

Charles L. Wilkerson ◽

Vishnu C. Ramani ◽

Nasim A. Barzanian ◽

...

Keyword(s):

Tumor Cells ◽

Circulating Tumor Cells ◽

Cancer Cell ◽

Blood Cells ◽

Liquid Biopsy ◽

White Blood Cells ◽

Automated System ◽

Cell Recovery ◽

Blood Draw ◽

Multiple Tumor

Tumor tissue biopsies are invasive, costly, and collect a limited cell population not completely reflective of patient cancer cell diversity. Circulating tumor cells (CTCs) can be isolated from a simple blood draw and may be representative of the diverse biology from multiple tumor sites. The VTX-1 Liquid Biopsy System was designed to automate the isolation of clinically relevant CTC populations, making the CTCs available for easy analysis. We present here the transition from a cutting-edge microfluidic innovation in the lab to a commercial, automated system for isolating CTCs directly from whole blood. As the technology evolved into a commercial system, flexible polydimethylsiloxane microfluidic chips were replaced by rigid poly(methyl methacrylate) chips for a 2.2-fold increase in cell recovery. Automating the fluidic processing with the VTX-1 further improved cancer cell recovery by nearly 1.4-fold, with a 2.8-fold decrease in contaminating white blood cells and overall improved reproducibility. Two isolation protocols were optimized that favor either the cancer cell recovery (up to 71.6% recovery) or sample purity (≤100 white blood cells/mL). The VTX-1’s performance was further tested with three different spiked breast or lung cancer cell lines, with 69.0% to 79.5% cell recovery. Finally, several cancer research applications are presented using the commercial VTX-1 system.

Download Full-text

Clonal origin of a T cell lymphoproliferative malignancy

Blood ◽

10.1182/blood.v52.1.69.69 ◽

1978 ◽

Vol 52 (1) ◽

pp. 69-76 ◽

Cited By ~ 9

Author(s):

PA Stryckmans ◽

L Debusscher ◽

C Heyder-Bruckner ◽

R Heimann ◽

IM Mandelbaum ◽

...

Keyword(s):

T Cells ◽

T Cell ◽

Red Blood Cells ◽

Tumor Cells ◽

Blood Cells ◽

Mononuclear Cells ◽

Polymorphonuclear Cells ◽

Clonal Origin ◽

Glucose 6 Phosphate Dehydrogenase ◽

Cell Malignancy

Abstract A woman with a T cell lymphoproliferative malignacy and heterozhgosity at the X chromosome-linked locus for glucose-6-phosphate dehydrogenase (G-6PD) isoenzymes was studied to find the clonal origin of her circulating neoplastic T cells. The red blood cells, polymorphonuclear cells, whole mononuclear cells, and T cell-depleted mononuclear cells contained both A and B isoenzymes of G-6-PD. In contrast, the tumor cells, separated by using their capacity to form rosettes with sheep red blood cells, contained only the B isoenzyme of G-6-PD. This observation strongly suggests the monoclonality of this T cell malignancy.

Download Full-text